ClinicalTrialsFinder

Methyl CpG Binding Protein 2 (MECP2) Duplication Syndrome Clinical Trials in Dijon

1 recruitingDijon, France

Showing 1–1 of 1 trials

Recruiting
Phase 1Phase 2

ATTUNE: A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Intrathecally-Administered ION440 in Participants With Methyl CpG Binding Protein 2 (MECP2) Duplication Syndrome (MDS)

Methyl CpG Binding Protein 2 (MECP2) Duplication Syndrome
Ionis Pharmaceuticals, Inc.48 enrolled11 locationsNCT06430385